Does Regence Cover Forteo? Teriparatide Coverage, Prior Authorization, and Cost

How Regence Classifies Forteo on Its Formulary

Regence BlueCross BlueShield places Forteo (teriparatide) on its specialty pharmacy tier across most commercial, individual, and Medicare Advantage formularies. This classification reflects the drug's injectable delivery, cold-chain storage requirements, and high acquisition cost.

Specialty-tier placement means Forteo is not dispensed at a standard retail pharmacy. Instead, Regence directs members to its preferred specialty pharmacy network, which handles the medication's temperature-controlled shipping and patient education requirements. The FDA-approved prescribing information for Forteo specifies that the drug must be refrigerated at 2-8°C and administered via subcutaneous injection daily, making specialty handling a medical necessity rather than an administrative preference [1].

Formulary placement can shift between plan years. Regence updates its formulary annually, and some employer-sponsored plans use custom formularies that differ from the standard commercial list. Members should verify their specific formulary through the Regence member portal or by calling the number on their insurance card before assuming coverage terms. The distinction matters: a plan that classifies Forteo under "specialty injectable" benefits may apply different cost-sharing rules than one that routes it through the medical benefit for provider-administered medications.

Regence operates across multiple states including Oregon, Washington, Utah, and Idaho, and formulary specifics can differ by state due to varying regulatory requirements and network contracts.

Prior Authorization Requirements for Forteo Under Regence

Every Regence plan that covers Forteo requires prior authorization before the first fill. This is not optional. Without prior authorization approval, the specialty pharmacy will reject the claim at the point of sale.

The prior authorization process for Forteo typically requires documentation of several clinical criteria. Prescribers must demonstrate that the patient has a confirmed diagnosis of osteoporosis, usually defined as a DXA T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip, or a history of fragility fracture. The International Society for Clinical Densitometry (ISCD) guidelines provide the diagnostic framework that most insurers reference when evaluating these requests [2].

Regence also requires evidence of step therapy compliance. The patient must have tried and failed, or have a documented contraindication to, at least one first-line oral bisphosphonate. Alendronate (Fosamax) and risedronate (Actonel) are the most commonly required step-therapy agents. "Failure" can mean continued bone loss on DXA despite 12 or more months of adherent bisphosphonate therapy, a new fracture while on treatment, or documented intolerance such as esophageal ulceration or severe gastrointestinal side effects.

A 2020 analysis published in the Journal of Bone and Mineral Research found that prior authorization requirements for anabolic osteoporosis agents delayed treatment initiation by a median of 34 days compared to therapies without such requirements [3]. For patients with recent vertebral fractures, this delay carries real clinical consequences: the American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend initiating anabolic therapy within weeks of a fragility fracture in very high-risk patients rather than starting with antiresorptive agents [4].

Which Diagnoses Qualify for Forteo Coverage Through Regence

Regence aligns its approved indications for Forteo with the FDA-approved label. Three primary diagnoses qualify.

Postmenopausal osteoporosis with high fracture risk is the most common approved indication. The FDA defines "high fracture risk" as a history of osteoporotic fracture, multiple risk factors for fracture, or failure of previous osteoporosis therapy [1]. Regence interprets this through its step-therapy lens, requiring prior bisphosphonate use in most cases.

Glucocorticoid-induced osteoporosis (GIO) represents the second qualifying diagnosis. Patients taking systemic corticosteroids equivalent to 5 mg or more of prednisone daily for three months or longer face accelerated bone loss. The American College of Rheumatology 2022 guidelines recommend teriparatide as a first-line option for patients at high fracture risk on chronic glucocorticoids, particularly those aged 40 and older with a T-score below -2.5 or a prior fragility fracture [5]. Regence may waive the bisphosphonate step-therapy requirement for GIO if the prescriber documents the ACR guideline recommendation.

Male osteoporosis with high fracture risk rounds out the approved indications. The Endocrine Society clinical practice guideline on male osteoporosis notes that teriparatide increases lumbar spine BMD by 5.9% over 11 months in men with idiopathic or hypogonadal osteoporosis [6]. Regence typically applies the same step-therapy and prior authorization criteria for men as for postmenopausal women.

Off-label uses, including fracture healing acceleration or osteogenesis imperfecta in adults, are generally denied by Regence. Exceptions require a peer-to-peer review and compelling literature support.

Cost Breakdown: What You Will Pay for Forteo With Regence

The out-of-pocket cost for Forteo under Regence depends on four variables: plan type, formulary tier, deductible status, and whether the plan applies copay accumulator or maximizer programs. Understanding each variable prevents billing surprises.

On standard Regence commercial plans with a specialty copay tier, members can expect to pay between $50 and $150 per 28-day supply after meeting their deductible. High-deductible health plans (HDHPs) paired with health savings accounts may require the member to pay the full negotiated price until reaching the deductible, which can mean $3,000 or more for the first one or two fills.

Coinsurance-based plans present the highest cost exposure. A plan requiring 25% coinsurance on specialty drugs, applied to Forteo's approximate wholesale acquisition cost of $4,200 per month, yields a $1,050 monthly out-of-pocket obligation before any maximum-out-of-pocket cap applies. The Kaiser Family Foundation 2023 Employer Health Benefits Survey reported that 30% of covered workers in plans with specialty drug tiers face coinsurance rather than flat copays [7].

Copay accumulator programs add another layer of complexity. Some Regence plans have adopted accumulator adjustment programs that prevent manufacturer copay assistance from counting toward the member's deductible or out-of-pocket maximum. If your Regence plan uses an accumulator program, the Eli Lilly Forteo Savings Card may reduce your monthly out-of-pocket cost but will not help you reach your deductible faster. Check your plan's Summary of Benefits and Coverage (SBC) document for accumulator language.

For Medicare Advantage plans administered by Regence, Forteo falls under Part D specialty tier coverage. The Centers for Medicare & Medicaid Services (CMS) caps Part D out-of-pocket spending, and beginning in 2025, the Inflation Reduction Act's $2,000 annual out-of-pocket maximum for Part D drugs significantly reduces cumulative Forteo costs for Medicare beneficiaries [8]. Members can also opt into the Medicare Part D prescription payment plan, which spreads costs across monthly installments.

Step Therapy: The Bisphosphonate-First Requirement

Regence's step-therapy protocol for Forteo reflects a cost-containment strategy grounded in clinical guidelines. Oral bisphosphonates cost approximately $10 to $30 per month for generic alendronate versus $4,200 per month for Forteo. That 100-fold price difference drives the step-therapy mandate.

The clinical rationale is supported by guideline recommendations. The AACE/ACE 2020 postmenopausal osteoporosis guidelines stratify treatment by fracture risk category [4]. For patients at "high risk" (T-score between -2.5 and -3.0 without prior fractures), oral bisphosphonates remain first-line. Anabolic agents like teriparatide are recommended first-line only for "very high risk" patients: those with recent fractures (within 12 months), T-scores below -3.0, or fractures while on approved osteoporosis therapy.

However, the VERO trial challenged the bisphosphonate-first approach. Published in The Lancet in 2018, VERO (N=1,360) randomized postmenopausal women with severe osteoporosis to teriparatide versus risedronate and found that teriparatide reduced new vertebral fractures by 56% (relative risk 0.44 to 95% CI 0.29-0.68) and clinical fractures by 52% over 24 months [9]. This trial provides the strongest evidence that anabolic-first therapy is superior in high-risk populations, and it serves as a useful citation when appealing a step-therapy denial.

To satisfy the step-therapy requirement efficiently, prescribers should document one of the following in the prior authorization submission: at least 12 months of adherent bisphosphonate use with continued bone loss or fracture, documented GI intolerance (endoscopy reports strengthen the case), esophageal disorders such as Barrett's esophagus or stricture that contraindicate oral bisphosphonates, or inability to remain upright for 30 minutes after dosing due to disability or frailty.

How to Appeal a Forteo Denial From Regence

A denied prior authorization is not the end of the process. Regence members have the right to file an internal appeal, followed by an independent external review if the internal appeal is unsuccessful.

The internal appeal must be filed within 180 days of the denial for most Regence commercial plans. The appeal should include a letter of medical necessity from the prescribing physician, supporting DXA scan results, fracture history documentation, a list of previously tried osteoporosis medications with dates and outcomes, and citations from clinical guidelines supporting teriparatide use for the patient's specific risk profile.

Peer-to-peer review requests can accelerate the process. When a prescriber calls Regence's utilization management department and speaks directly with the reviewing physician, denials based on incomplete documentation are frequently overturned within 24 to 48 hours. The reviewing physician may not be an endocrinologist or rheumatologist, so prescribers should explain the clinical urgency in terms any internist would understand.

External review is available if the internal appeal fails. Under federal regulations established by the Affordable Care Act, Regence must allow members to request review by an independent review organization (IRO) [10]. The IRO's decision is binding on Regence. For Forteo appeals, external reviewers typically evaluate whether the insurer's step-therapy requirement is clinically appropriate given the individual patient's fracture risk.

State-specific protections may also apply. Oregon and Washington, two of Regence's largest markets, have enacted step-therapy override laws that require insurers to grant exceptions when the required first-line therapy is contraindicated, has been tried and failed, or is expected to be ineffective based on the patient's clinical history. Prescribers should cite the applicable state statute in appeal letters.

Forteo Alternatives Covered by Regence

If Forteo is denied or cost-prohibitive, Regence covers several alternative osteoporosis therapies with different coverage requirements and out-of-pocket costs.

Generic teriparatide became available in 2024 after Eli Lilly's patent exclusivity expired. Regence formularies have begun listing generic teriparatide at a lower specialty-tier copay than brand Forteo, though availability through specialty pharmacies is still expanding. Prescribers should specify "teriparatide" with "dispense as written" unchecked to allow generic substitution.

Tymlos (abaloparatide), a parathyroid hormone-related peptide analog, is covered by most Regence plans under similar prior authorization and step-therapy requirements as Forteo. The ACTIVE trial (N=2,463) demonstrated that abaloparatide reduced new vertebral fractures by 86% versus placebo at 18 months [11]. Its wholesale cost is comparable to Forteo.

Evenity (romosozumab), a sclerostin inhibitor administered as monthly subcutaneous injections for 12 months, is covered under Regence's medical benefit (not pharmacy benefit) when administered in a healthcare setting. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced clinical fractures by 27% compared with alendronate alone over a median 33-month follow-up period [12]. Regence typically requires prior authorization for Evenity with documentation of very high fracture risk, and a cardiovascular risk assessment due to the FDA's boxed warning regarding potential myocardial infarction and stroke risk.

Prolia (denosumab), a RANK ligand inhibitor given as a twice-yearly subcutaneous injection, occupies a different mechanistic category as an antiresorptive rather than anabolic agent. Regence covers Prolia under the medical benefit with prior authorization. At approximately $1,800 per injection (every six months), its annualized cost is lower than Forteo's, making it a common insurer-preferred alternative. The FREEDOM trial (N=7,868) demonstrated a 68% reduction in vertebral fractures over 36 months [13].

Specialty Pharmacy and Delivery Logistics

Regence requires Forteo to be dispensed through its preferred specialty pharmacy network. This is non-negotiable on most plans. The specialty pharmacy handles cold-chain shipping, which is necessary because teriparatide degrades at room temperature.

Members should expect to receive their Forteo delivery in an insulated package with cold packs. The delivery typically arrives within 3 to 5 business days after prior authorization approval. Refills are coordinated proactively: the specialty pharmacy will contact the member approximately 7 days before their current pen runs out to schedule the next shipment.

First-fill coordination can cause delays. The specialty pharmacy must verify benefits, confirm prior authorization approval, collect any applicable copay or coinsurance, and arrange delivery. New patients should allow 7 to 14 days from the date of prior authorization approval to receiving their first pen. Prescribers can reduce this timeline by submitting the prescription to the specialty pharmacy simultaneously with the prior authorization request rather than waiting for approval first.

Each Forteo pen contains a 28-day supply (28 daily doses of 20 mcg). The pen must be stored in the refrigerator between uses and should not be frozen. Members who travel should coordinate with the specialty pharmacy for travel-sized cold storage packs.

The 24-Month Treatment Window and What Comes After

The FDA limits Forteo treatment to 24 months based on preclinical data showing osteosarcoma in rats exposed to high-dose teriparatide for near-lifetime durations. While post-marketing surveillance has not confirmed an increased osteosarcoma risk in humans according to a 15-year pharmacovigilance analysis, the 24-month cap remains in the labeling [14].

Regence authorizes Forteo in 6- or 12-month intervals, requiring reauthorization to continue therapy up to the 24-month maximum. Each reauthorization may require updated clinical documentation, including interval DXA scans showing response to therapy.

What happens after 24 months matters as much as the treatment itself. Bone density gains from teriparatide are lost rapidly if no antiresorptive agent follows. The DATA-Switch study demonstrated that sequential therapy with denosumab after teriparatide produced continued BMD gains, while discontinuation without follow-on therapy led to significant bone loss within 12 months [15]. Prescribers should plan the transition to an antiresorptive agent before the Forteo course ends and submit prior authorization for the follow-on therapy in advance to avoid a gap.

Regence covers the transition to denosumab, zoledronic acid, or oral bisphosphonates after Forteo completion. Zoledronic acid (Reclast), given as a single annual IV infusion, is often the most convenient post-teriparatide option and is covered under the medical benefit with standard prior authorization.